Biotinylated Human CD30 / TNFRSF8, His Tag (CD0-H82E6) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2).
Predicted N-terminus: Phe 19
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 41.1 kDa. The protein migrates as 60-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human CD30 / TNFRSF8, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Anti-CD30 MAb, Human IgG1 at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD30, His Tag (Catalog # CD0-H82E6) with a linear range of 0.4-6.5 ng/mL.
Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.